Capping off a year in which it raised nearly $950 million in an up-sized IPO, Quintiles hauled in $1 billion in service revenue in the fourth quarter, a company first that sets the table for more growth in 2014.
Last year, Albany, NY, contract developer AMRI watched its founding CEO retire and its business model evolve, shifting its priorities to deliver a jump in revenue, and now the company believes it's on track for bigger growth in 2014.
Almost 10 years after closing a deal for the eClinical-focused Perceptive Informatics, CRO giant Parexel International is grafting its own name onto the subsidiary, part of a sweeping rebranding effort the company hopes will help nail down more partnerships.
Charles River Laboratories has pulled off a sweeping reorganization over the past few years, and the effort returned the preclinical CRO to revenue growth in 2013, setting the stage for another jump this year.
The global CRO market is likely to hit $23.6 billion this year, according to Industry Standard Research, an all-time high that will only be followed by faster growth.
Pharma giant AstraZeneca has pulled the plug on a fleet of its in-development drugs but let live a rheumatoid arthritis treatment being co-developed with Chinese CRO giant WuXi PharmaTech.
The U.K.'s Wellcome Trust is putting up about $4.1 million to fund a collaboration between CRO Selcia and Edinburgh University, under which the two will develop new treatments for sleeping sickness.
Last year, CRO BioClinica saw its most rapid growth in Europe, the company said, and now, as it prepares to join forces with CCBR-Synarc in its second merger in as many years, the clinical trial outfit plans to deepen its investment in the continent.
As more and more massive-selling biologics lose their patent protection, a new class of biosimilars is poised to blow up around the world, and the U.K.'s BioOutsource is amping up its capabilities to prepare for the boom.
Global CRO Covance boosted its revenue by about 11% last quarter, capping off a banner year in which the company outstripped its financial targets.
Canadian CRO Algorithme Pharma has expanded its Montreal clinic to include a dedicated unit for complex trials, adding 41 beds to its flagship facility.
CRO conglomerate inVentiv Health has extended its deal with Swedish outfit NeuroVive Pharmaceutical, and the contract researcher says its ability to tailor its platform to developers of all sizes make it an ideal partner for drugmakers on the come-up.
Australian CRO Novotech is heading west with its global expansion effort, opening up shop in South Africa to broaden its access to diverse patient populations.
The U.K.'s Ergomed takes a more hands-on approach to contract development than many CROs, and the company has inked another risk-sharing partnership, teaming up with Spain's Ferrer to progress an insomnia treatment.
After a hiccup in new business alarmed investors and overshadowed steady gains, Parexel righted the ship in its second fiscal quarter, boosting its new contracts and growing revenue by about 15%.
India's GVK Biosciences has signed a deal to acquire Aragen Bioscience, a California-headquartered preclinical CRO, in an effort to tap into the booming demand for biologics development and expand its stateside market.
Clinical trial software outfits Datatrak and Clinverse have joined forces to provide what they say is the industry's first end-to-end technology for financing studies.
Years of lax regulations helped India build a booming market for clinical trials, but a recent move to strengthen patient protections has deflated demand, and last year saw just 19 studies get underway in the country, The Pharma Letter reports.
Belgium's fast-growing Genae has expanded into Germany, opening up an outpost in Frankfurt to tap one of Europe's largest medical device markets.
ResearchDx, one of the few outfits devoted to contract test making, has extended its operation to include the Middle East, a region the company said is home to a growing biotech market.